Biosimilars in oncology

by Tabernero, Josep
Published in ESMO Open (2018)

All change: closing the gender gap in oncology

by Tabernero, Josep
Published in ESMO Open (2018)

Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations

by Tabernero, Josep
Published in ESMO Open (2019)

Molecular Dissection of Microsatellite Instable Colorectal Cancer

by Vilar, Eduardo, Tabernero, Josep
Published 2013

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life

by Ciardiello, Fortunato, Tabernero, Josep
Published in ESMO Open (2016)

Back-to-back discovery, co-precision, and prevention

by Casadei, Barbara, Tabernero, Josep
Published in Eur Heart J Qual Care Clin Outcomes (2020)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

by Markman, Ben, Dienstmann, Rodrigo, Tabernero, Josep
Published 2010

Multi-target angiokinase inhibitors to fight resistance

by Casanovas, Oriol, Salazar, Ramon, Tabernero, Josep
Published in Cell Cycle (2014)

Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy

by Verdaguer, Helena, Tabernero, Josep, Macarulla, Teresa
Published in Ther Adv Med Oncol (2016)

Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test

by Dienstmann, Rodrigo, Rodon, Jordi, Tabernero, Josep
Published in Mol Oncol (2014)

Pushing the envelope in the mTOR pathway. The second generation of inhibitors

by Vilar, Eduardo, Perez-Garcia, Jose, Tabernero, Josep
Published 2011

Micromanaging the classification of colon cancer. The role of the microRNAome

by Vilar, Eduardo, Tabernero, Josep, Gruber, Stephen B.
Published 2011

Accomplishments in 2008 in the Treatment of Advanced Metastatic Colorectal Cancer

by Goldberg, Richard M., Meropol, Neal J., Tabernero, Josep
Published 2009

Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs

by Dienstmann, Rodrigo, Braña, Irene, Rodon, Jordi, Tabernero, Josep
Published 2011

Treatment-related mortality with aflibercept in cancer patients

by Tabernero, Josep, Hitier, Simon, Derobert, Eric, Van Cutsem, Eric
Published 2014

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer

by Dienstmann, Rodrigo, De Dosso, Sara, Felip, Enriqueta, Tabernero, Josep
Published in Mol Oncol (2011)

How I treat gastric adenocarcinoma

by Alsina, Maria, Miquel, Josep Maria, Diez, Marc, Castro, Sandra, Tabernero, Josep
Published in ESMO Open (2019)

New clinical trial designs in the era of precision medicine

by Garralda, Elena, Dienstmann, Rodrigo, Piris‐Giménez, Alejandro, Braña, Irene, Rodon, Jordi, Tabernero, Josep
Published in Mol Oncol (2019)

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial

by Tabernero, Josep, Kunzmann, Volker, Scheithauer, Werner, Reni, Michele, Shiansong Li, Jack, Ferrara, Stefano, Djazouli, Kamel
Published in Onco Targets Ther (2017)

Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology

by Giuliani, Rosa, Tabernero, Josep, Cardoso, Fatima, McGregor, Keith Hanson, Vyas, Malvika, de Vries, Elisabeth G E
Published in ESMO Open (2019)